Trade negotiations between India and the United States have reached a difficult stage, raising the risk that businesses will face continued tariff uncertainty. India’s finance minister, Nirmala Sitharaman, said the talks had reached a plateau where further concessions would be difficult, according to CNBC.
The dispute centers partly on the bilateral goods imbalance and market access. U.S. officials want greater access for American products, while India is seeking tariff treatment that keeps its exports competitive in the U.S. market. CNBC reported a U.S. goods deficit with India of $58.42 billion in 2025 and $28.4 billion in the first seven months of 2026.
Official U.S. documents show that the two governments had announced a joint trade framework in February and continued bilateral agreement discussions during a U.S. Trade Representative visit to New Delhi in June. The latest public comments indicate that the broad political commitment has not resolved the most difficult commercial terms.
For investors, the risk is sector-specific rather than uniform. Indian exporters that depend heavily on U.S. demand face uncertainty over relative tariff treatment. U.S. companies seeking access to India could benefit from a deal, but may continue to face barriers if negotiations remain stalled. Pharmaceuticals and smartphones deserve particular attention because CNBC reported that substantial portions of those exports were outside the current 10% duty.
The absence of an imminent agreement does not mean negotiations have failed. It does mean that investors should avoid pricing in full tariff relief until detailed, enforceable terms are published by both governments.